Anti-diabetes drug market: not an industry panacea

Strong growth in the market for anti-diabetes drugs will not outweigh decline in the broader market for drugs for the treatment of cardiovascular and metabolic conditions, according to a report from market research firm Datamonitor. The latter will peak across the ‘seven major’ regions in 2011 and then begin to decline due to generic erosion, with total sales falling from $105 billion (£65 billion) in 2009 to $101 billion in 2019. The market for drugs for the treatment of dyslipidemia and hypertension, in particular, is set to become almost entirely dominated by generics. (more…)

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Bayer and Evogene to work together on GM wheat

German chemical group Bayer has said it will pay $20 million (£13 million) as part of a five-year deal with Israeli plant sciences company Evogene that will see the two develop new genetically modified wheat varieties. In a separate deal, Bayer will buy a $12 million stake in Evogene at a price of $7 per share. The aim of the project will be to improve key characteristics such as yield, drought tolerance and fertiliser utilisation. (more…)

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

We’ve had a look at some of the financial results for the third quarter of 2010 already. Here’s the rest of the data. (All percentage changes are based on the same period last year.)

PHARMACEUTICAL

AstraZeneca made sales of $7.9 billion (£5 billion), a 4 per cent decrease. Operating income decreased 25 per cent to $2.4 billion.

Bayer made sales of €8.6 billion (£7.3 billion), a 16 per cent increase. Operating income decreased 14 per cent to €560 million. (more…)

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

PHARMACEUTICAL

Sekisui buys Genzyme diagnostics

Japanese chemical group Sekisui has agreed to buy the diagnostic products business at Genzyme for $265 million (£168 million) in cash. Sekisui has agreed to offer employment to all 575 employees involved upon closing. In addition, it is planning to continue operations at all the current sites. In 2009, the Genzyme diagnostics business generated sales of $167 million. (more…)

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

« Previous Page